Neurovirulence safety testing of mumps vaccines--historical perspective and current status

S A Rubin1, M A Afzal

  • 1Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, MD 20892, USA. steven.rubin@fda.hhs.gov

Vaccine
|February 22, 2011
PubMed

Insights

Live viral vaccines require safety testing for neurotoxicity. Current monkey-based tests for mumps vaccines are unreliable, prompting development of alternative methods to ensure human safety.

Area of Science:

  • Virology
  • Vaccinology
  • Neuroscience

Background:

  • Live, attenuated viral vaccines are derived from wild-type viruses, necessitating pre-clinical neurovirulence safety testing to ensure the absence of residual neurotoxicity.
  • Mumps virus, being highly neurotropic, undergoes neurovirulence safety testing in monkeys.

Observation:

  • Laboratory studies indicate that current monkey-based neurovirulence testing may not accurately differentiate between mumps virus strains with varying neurovirulence potential in humans.
  • Some mumps vaccines deemed neuroattenuated in monkeys later exhibited neurovirulence in humans when administered in large quantities.

Findings:

  • Over the last decade, significant efforts have focused on replacing monkey-based neurovirulence safety testing with more informative alternative methods.
  • This review examines the current state of mumps vaccine neurovirulence safety testing and evaluates approved and emerging alternative models.

Implications:

  • Developing reliable alternative methods for mumps vaccine neurovirulence testing is crucial for enhancing vaccine safety and efficacy.
  • Advancements in alternative testing models promise more accurate prediction of vaccine neurovirulence in humans, improving public health outcomes.

Related Concept Videos

Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
Smallpox01:24

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
Viral Meningitis01:18

Viral Meningitis

Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...
Vaccinations01:51

Vaccinations

Overview
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...